Morand, Eric http://orcid.org/0000-0002-9507-3338
Merola, Joseph F.
Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Gladman, Dafna http://orcid.org/0000-0002-9074-0592
Fleischmann, Roy http://orcid.org/0000-0002-6630-1477
Article History
Accepted: 9 February 2024
First Online: 11 March 2024
Competing interests
: R.F. declares that he has acted as a consultant for AbbVie, Amgen, Atomwise, BMS, Galvani, Galapagos, Gilead, GSK, Immunovant, Janssen, Eli Lilly. Novartis, Pfizer, UCB and Vyne; serves on the data safety monitoring boards for Celltrion, EMDSerano and Kiniksa; and has received clinical trial grants from AbbVie, Arthrosi, Biogen, BMS, Eli Lilly, Flexion, Galvani, Genentech, Gilead, GSK, Horizon, Janssen, Novartis, Oletec, Priovant, Scipher, Selecta, UCB and Viela. Y.T. declares that he has received speaking fees and/or honoraria from AbbVie, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers, Chugai, Daiichi-Sankyo, Eli Lilly, Eisai, Gilead, GlaxoSmithKline, Mitsubishi-Tanabe and Pfizer; and research grants from Asahi-Kasei, AbbVie, Behringer-Ingelheim, Chugai, Daiichi-Sankyo, Eisai and Takeda. D.G. declares that she has received grant support from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB; and consulting fees from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. E.M. declares that he has received research grants from AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, GSK, Janssen, Takeda and UCB; and advisory and/or honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, GSK, Gilead, Novartis, Takeda and Zenas. J.F.M. declares that he has acted as a consultant for AbbVie, Biogen, Celgene, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer and UCB.